Novartis reported a 7% increase in net sales in Q3, with a 27% rise in operating income and a 25% increase in net profit. Key brands like Kisqali and Pluvicto drove growth. The FDA approved Rhapsido for chronic spontaneous urticaria. Positive results were seen in studies for Ianalumab and Pluvicto. Operating margin remained stable at 39.3%.

CEO Vas Narasimhan commented on Novartis’ strong Q3 financial performance, highlighting growth drivers like Kisqali and Pluvicto, FDA approvals for Rhapsido, and positive study results for Ianalumab. The company aims to meet its 2025 forecast and strengthen its pipeline through recent transactions. Novartis remains focused on innovative medicines in key therapeutic areas.

In Q3, Novartis saw a 8% increase in net sales, a 24% increase in operating income, and a 23% increase in net profit. Key brands like Kisqali, Kesimpta, and Pluvicto showed strong sales growth. The company also achieved positive milestones in innovation, including FDA approvals and positive study results for various drugs addressing different medical conditions. Novartis continues to focus on accelerating growth and delivering value to shareholders.

Read more at GlobeNewswire: Novartis verzeichnet im dritten Quartal solide Steigerungen